On February 15, 2021 Kuraray Co., Ltd. (hereinafter "Kuraray" or "the Company") reported details of outstanding items in connection with the Company’s decision to issue share purchase warrants as part of a stock-linked compensation plan (Press release, Kuraray, FEB 15, 2021, https://pdf.irpocket.com/C3405/ng2K/nikM/NTCq.pdf [SID1234575067]). The decision to offer share purchase warrants, identified as "Kuraray Co., Ltd. Share Purchase Warrants issued in February 2021" was first made at a Board of Directors’ meeting held on January 20, 2021. Brief details of outstanding items are provided as follows.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Total number of allotted share purchase warrants 197 units (the number of shares to be granted per share purchase warrant is 500)

2. Parties eligible for allotment (hereinafter "Rights Holders") and number of allotted
share purchase warrants

3. Type and number of shares to be issued upon the exercise of share purchase warrants 98,500 shares of Kuraray common stock 4. Total payment due upon exercise of share purchase warrants Payment per share purchase warrant ¥587,000 (Payment per share ¥1,174)